clioquinol has been researched along with Benign Neoplasms in 16 studies
Clioquinol: A potentially neurotoxic 8-hydroxyquinoline derivative long used as a topical anti-infective, intestinal antiamebic, and vaginal trichomonacide. The oral preparation has been shown to cause subacute myelo-optic neuropathy and has been banned worldwide.
5-chloro-7-iodoquinolin-8-ol : A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by chlorine and iodine, respectively. It has antibacterial and atifungal properties, and is used in creams for the treatment of skin infections. It has also been investigated as a chelator of copper and zinc ions for the possible treatment of Alzheimer's disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Recently it was reported clioquinol can inhibit the proteasomal chymotrypsin-like activity and induce apoptotic cell death in leukemia and myeloma." | 7.77 | Proteasome inhibitor clioquinol as a candidate drug in prophylaxis and treatment of acute graft-versus-host disease. ( Liang, Y; Liu, H; Mao, X, 2011) |
| " Recently it was reported clioquinol can inhibit the proteasomal chymotrypsin-like activity and induce apoptotic cell death in leukemia and myeloma." | 3.77 | Proteasome inhibitor clioquinol as a candidate drug in prophylaxis and treatment of acute graft-versus-host disease. ( Liang, Y; Liu, H; Mao, X, 2011) |
| "Clioquinol acts as a copper and zinc ionophore, a proteasome inhibitor, an anti-angiogenesis agent, and is an inhibitor of key signal transduction pathways responsible for its growth-inhibitory activity and cytotoxicity in cancer cells preclinically." | 2.66 | Feasibility of Repurposing Clioquinol for Cancer Therapy. ( Abdullah, Y; Dou, QP; Khan, H; Khan, R, 2020) |
| "Its anti-cancer activity relates, at least in part, to its ability to inhibit the proteasome through mechanisms dependent and independent of its ability to bind heavy metals such as copper." | 2.47 | Clioquinol - a novel copper-dependent and independent proteasome inhibitor. ( Schimmer, AD, 2011) |
| "The anticancer activity of DDC is dependent on complexation with copper to form copper bis-diethyldithiocarbamate (Cu(DDC)2), a highly insoluble complex that has not been possible to develop for indications requiring parenteral administration." | 1.43 | Nanoscale Reaction Vessels Designed for Synthesis of Copper-Drug Complexes Suitable for Preclinical Development. ( Anantha, M; Backstrom, I; Bally, MB; Chen, K; Edwards, K; Leung, A; Malhotra, A; Wehbe, M, 2016) |
| "The MCF-7 human cancer cell line was applied as a cell model system." | 1.38 | Zinc at cytotoxic concentrations affects posttranscriptional events of gene expression in cancer cells. ( Ding, WQ; Taggart, JE; Yu, H; Zhang, XX; Zheng, J, 2012) |
| "Clioquinol has been shown to have anticancer activity both in vitro and in vivo." | 1.37 | Nitroxoline (8-hydroxy-5-nitroquinoline) is more a potent anti-cancer agent than clioquinol (5-chloro-7-iodo-8-quinoline). ( Benbrook, DM; Ding, WQ; Jiang, H; Lind, SE; Taggart, JE; Zhang, X, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.25) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 11 (68.75) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Khan, R | 1 |
| Khan, H | 1 |
| Abdullah, Y | 1 |
| Dou, QP | 3 |
| Perez, DR | 1 |
| Sklar, LA | 1 |
| Chigaev, A | 1 |
| Pushie, MJ | 1 |
| Nienaber, KH | 1 |
| Summers, KL | 1 |
| Cotelesage, JJ | 1 |
| Ponomarenko, O | 1 |
| Nichol, HK | 1 |
| Pickering, IJ | 1 |
| George, GN | 1 |
| Wehbe, M | 1 |
| Anantha, M | 1 |
| Backstrom, I | 1 |
| Leung, A | 1 |
| Chen, K | 1 |
| Malhotra, A | 1 |
| Edwards, K | 1 |
| Bally, MB | 1 |
| Mao, H | 1 |
| Wang, M | 1 |
| Cao, B | 1 |
| Zhou, H | 1 |
| Zhang, Z | 1 |
| Mao, X | 2 |
| Mitrović, A | 1 |
| Kljun, J | 1 |
| Sosič, I | 1 |
| Gobec, S | 1 |
| Turel, I | 1 |
| Kos, J | 1 |
| Zhai, S | 1 |
| Yang, L | 1 |
| Cui, QC | 1 |
| Sun, Y | 1 |
| Yan, B | 2 |
| Liang, Y | 1 |
| Liu, H | 1 |
| Schimmer, AD | 2 |
| Ruschak, AM | 1 |
| Slassi, M | 1 |
| Kay, LE | 1 |
| Jiang, H | 1 |
| Taggart, JE | 2 |
| Zhang, X | 1 |
| Benbrook, DM | 1 |
| Lind, SE | 2 |
| Ding, WQ | 3 |
| Zheng, J | 1 |
| Zhang, XX | 1 |
| Yu, H | 1 |
| Liu, B | 1 |
| Vaught, JL | 1 |
| Palmiter, RD | 1 |
| Daniel, KG | 1 |
| Chen, D | 1 |
| Yanagimoto, T | 1 |
| Kashiwagi, N | 1 |
| Kleibel, F | 1 |
5 reviews available for clioquinol and Benign Neoplasms
| Article | Year |
|---|---|
Feasibility of Repurposing Clioquinol for Cancer Therapy.
Topics: Cell Line, Tumor; Clioquinol; Drug Repositioning; Feasibility Studies; Female; Humans; Male; Neoplas | 2020 |
Clioquinol: To harm or heal.
Topics: Animals; Anti-Infective Agents; Asian People; ATP-Binding Cassette Transporters; Clioquinol; Cyclic | 2019 |
Clioquinol - a novel copper-dependent and independent proteasome inhibitor.
Topics: Animals; Antineoplastic Agents; Clioquinol; Copper; Humans; Neoplasms; Protease Inhibitors; Proteaso | 2011 |
Novel proteasome inhibitors to overcome bortezomib resistance.
Topics: Allosteric Site; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tu | 2011 |
Copper-binding compounds as proteasome inhibitors and apoptosis inducers in human cancer.
Topics: Antineoplastic Agents; Apoptosis; Clioquinol; Copper; Humans; Neoplasms; Neovascularization, Patholo | 2007 |
11 other studies available for clioquinol and Benign Neoplasms
| Article | Year |
|---|---|
The solution structure of the copper clioquinol complex.
Topics: Alzheimer Disease; Chelating Agents; Clioquinol; Copper; Humans; Molecular Structure; Neoplasms; Sol | 2014 |
Nanoscale Reaction Vessels Designed for Synthesis of Copper-Drug Complexes Suitable for Preclinical Development.
Topics: Animals; Antineoplastic Agents; Antioxidants; Benzothiazoles; Cell Survival; Clioquinol; Copper; Dit | 2016 |
Interferon-stimulated gene 15 induces cancer cell death by suppressing the NF-κB signaling pathway.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Clioquinol; Cytokines; Endopeptidases; Fem | 2016 |
Clioquinol-ruthenium complex impairs tumour cell invasion by inhibiting cathepsin B activity.
Topics: Antineoplastic Agents; Cathepsin B; Cell Line, Tumor; Clioquinol; Cymenes; Enzyme Inhibitors; Humans | 2016 |
Tumor cellular proteasome inhibition and growth suppression by 8-hydroxyquinoline and clioquinol requires their capabilities to bind copper and transport copper into cells.
Topics: Antineoplastic Agents; Biological Transport; Cell Proliferation; Clioquinol; Copper; Drug Screening | 2010 |
Proteasome inhibitor clioquinol as a candidate drug in prophylaxis and treatment of acute graft-versus-host disease.
Topics: Bone Marrow Transplantation; Clioquinol; Enzyme Inhibitors; Graft vs Host Disease; Hematopoietic Ste | 2011 |
Nitroxoline (8-hydroxy-5-nitroquinoline) is more a potent anti-cancer agent than clioquinol (5-chloro-7-iodo-8-quinoline).
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Clioquinol; Drug Screening Assays, Antitumor | 2011 |
Zinc at cytotoxic concentrations affects posttranscriptional events of gene expression in cancer cells.
Topics: Cell Line, Tumor; Clioquinol; DEAD-box RNA Helicases; Gene Expression; Humans; MicroRNAs; Neoplasms; | 2012 |
Clioquinol and docosahexaenoic acid act synergistically to kill tumor cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Clioquinol; Docosahexae | 2006 |
Empirical Bayes methods for smoothing data and for simultaneous estimation of many parameters.
Topics: Bayes Theorem; Clioquinol; Cohort Studies; Female; Humans; Japan; Likelihood Functions; Male; Neopla | 1990 |
[The development and treatment of radiogenic diarrhea].
Topics: Adult; Aged; Clioquinol; Diarrhea; Enterocolitis, Pseudomembranous; Female; Humans; Male; Middle Age | 1966 |